Premium
Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient
Author(s) -
Joo Su Jin,
Yildirim Inci,
Stenger Elizabeth O.,
Anderson Evan J.
Publication year - 2019
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13425
Subject(s) - medicine , sirolimus , cardiac tamponade , pneumonitis , pericardial effusion , interstitial pneumonitis , hematopoietic stem cell transplantation , discovery and development of mtor inhibitors , tamponade , graft versus host disease , haematopoiesis , stem cell , adverse effect , surgery , transplantation , pi3k/akt/mtor pathway , lung , respiratory disease , apoptosis , biochemistry , chemistry , biology , genetics
Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a potent immunosuppressant that is increasingly used in prevention and treatment of graft‐vs‐host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) patients. However, data regarding its adverse effects in HSCT patients remain limited. We describe an 18‐year‐old HSCT patient with a history of invasive fungal infection, who developed pericardial effusion with cardiac tamponade and interstitial pneumonitis while receiving sirolimus for GVHD prophylaxis. Our case illustrates potentially life‐threatening complications of sirolimus use in allogeneic HSCT patients.